SEARCH

SEARCH BY CITATION

References

  • 1
    Du Vigneaud V. Trail of sulfur research: from insulin to oxytocin. Science 1956; 123: 96774.
  • 2
    West R, West S, Simons R, McGlennan A. Impact of dose finding studies on anaesthetic prescribing practice of oxytocin in the United Kingdom. Anaesthesia 2013; 68: 102125.
  • 3
    Centre for Maternal and Child Enquiries (CMACE). Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer: 2006–08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. British Journal of Obstetrics and Gynaecology 2011; 118: 1203.
  • 4
    Nordstrom L, Fogelstam K, Fridman G, Larsson A, Rydhstroem H. Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. British Journal of Obstetrics and Gynaecology 1997; 104: 7816.
  • 5
    Johnstone M. The cardiovascular effects of oxytocic drugs. British Journal of Anaesthesia 1972; 44: 82634.
  • 6
    Pinder AJ, Dresner M, Calow C, O'Riordan J, Johnson R. Hameodynamic changes caused by oxytocin during caesarean section under spinal anaesthesia. International Journal of Obstetric Anesthesia 2002; 11: 1569.
  • 7
    Svanstrom MC, Biber B, Hanes M, Johansson G, Naslund U, Balfors EM. Signs of myocardial ischaemia after injection of oxytocin: a randomised double blind comparison of oxytocin and methylergometrine during caesarean section. British Journal of Anaesthesia 2008; 11: 6839.
  • 8
    Lewis G, ed. Why Mothers Die 1997–1999. The Fifth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. London: RCOG Press, 2001.
  • 9
    Bolton TJ, Randall K, Yentis SM. Effect of the Confidential Enquiries into Maternal Deaths on the use of Syntocinon® at Caesarean section in the UK. Anaesthesia 2003; 58: 26179.
  • 10
    Royal College of Obstetrics and Gynaecology. Post partum haemorrhage prevention and management. Green-top guideline 52. London: RCOG press, 2009.
  • 11
    Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press http://www.medicinescomplete.com/mc/bnf/current/PHP4781-syntocinon.htm?q=oxytocin&t=search&ss=text&p=3#PHP4781-syntocinon (accessed 15/04/2013).
  • 12
    Thomas JS, Koh SH, Cooper GM. Haemodynamic effects of oxytocin given as an i.v. bolus or infusion on women undergoing Caesarean section. British Journal of Anaesthesia 2007; 98: 1169.
  • 13
    Bhattacharya S, Ghosh S, Ray D, Mallik S, Laha A. Oxytocin administration during cesarean delivery: randomised controlled trial to compare intravenous bolus with intravenous infusion regime. Journal of Anesthesiology Clinical Pharmacology 2013; 29: 325.
  • 14
    Butwick AJ, Coleman L, Cohen SE, Riley ET, Carvalho B. Minimum effective bolus dose of oxytocin during elective Caesarean delivery. British Journal of Anaesthesia 2010; 104: 33843.
  • 15
    George RB, McKeen D, Chaplin AC, McLeod L. Up-down determination of the ED90 of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing Cesarean delivery. Canadian Journal of Anesthesia 2010; 57: 57882.
  • 16
    Carvalho JCA, Balki M, Kingdom J, Windrim R. Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstetrics and Gynecology 2004; 104: 100510.
  • 17
    Balki M, Ronayne M, Davies S, et al. Minimum oxytocin requirement after cesarean delivery for labour arrest. Obstetrics and Gynecology 2006; 107: 4550.
  • 18
    Robinson C, Schumann R, Zhang P, Young RC. Oxytocin induced desensitization of the oxytocin receptor. American Journal of Obstetrics and Gynecology 2003; 188: 497502.
  • 19
    Sheehan SR, Montgomery AA, Carey M, et al. Oxytocin bolus versus bolus and infusion for control of blood loss at elective caesarean section: double blind, placebo controlled, randomised trial. British Medical Journal 2011; 343: 111.
  • 20
    Sweeny G, Holbrook AM, Levine M, et al. Pharmacokinetics of carbetocin, a long acting oxytocin analogue, in non-pregnant women. Current Therapeutic Research 1990; 47: 52840.
  • 21
    Attilakos G, Psaroudakis D, Ash J, et al. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double blinded randomised trial. British Journal of Obstetrics and Gynaecology 2010; 117: 92936.
  • 22
    Holleboom CAG, Van Eyck J, Koenen SV, et al. Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands. Archives of Gynecology and Obstetrics 2013; 287: 11117.
  • 23
    Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews 2012; 4: CD005457.
  • 24
    Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press http://www.medicinescomplete.com/mc/bnf/current/PHP4765-carbetocin.htm (accessed 15/04/2013).
  • 25
    Moertl MG, Friedrich S, Kraschl J, Wadsack C, Lang U, Schlembach D. Haemodynamic effects of carbetocin and oxytocin given as intravenous bolus on women undergoing caesarean delivery: a randomised trial. British Journal of Obstetrics and Gynaecology 2011; 118: 134956.
  • 26
    Tsen LC, Balki M. Oxytocin protocols during caesarean delivery: time to acknowledge the risk/benefit ratio? International Journal of Obstetric Anesthesia 2010; 19: 2435.